Biomakers was created to address a fundamental problem in oncology: global drug and diagnostic development has relied on data that captures only a narrow slice of human genetic diversity. To close this gap, the company is building the missing precision data infrastructure by focusing where it matters most for scientific completeness, Latin America’s uniquely rich and underrepresented genomic landscape.
